Wen-Jing Gao, Jing-Jing Yang, Meng Li, Ya-Nan Wen, Yi-Fan Jiao, Ning LE, Yu-Chen Liu, Nan Wang, Sai Huang, Li-Ping Dou
OBJECTIVE: To investigate the efficacy and safety of Venetoclax combined with CACAG regimen in treatment of patients with refractory/relapse acute myeloid leukemia(R/R AML). METHODS: The study was a singlecenter prospective clinical trial. The enrolled patients met the criteria for R/R AML. Treatment included Azacidine(75 mg/m2 ,d 1-7), Ara-C (75-100 mg/m2 , q12h, d 1-5), Aclacinomycin(20 mg d1,d3,d5), Chidamide(30 mg d1,d4), Venetoclax(100 mg d1, 200 mg d2, 400 mg d3-d14, in combination with Triazole Drug, reduced to 100 mg/d), and granulocyte colony-stimulating factor (300 μg /d until neutrophil recovery)...
February 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi